GLP-1 Medications: What They Are, How They Work, and Why They're Changing Lives
You've probably heard the names — Ozempic, Wegovy, Mounjaro, Zepbound. Maybe a friend is taking one. Maybe you've seen the headlines. And maybe you're wondering: Is this real? Is this safe? Is this right for me?
Let me give you the full picture — not the hype, not the fear, just the science. As a triple board-certified endocrinologist and obesity medicine specialist, I've been prescribing these medications and watching them transform lives. Here's everything you need to know.
What Is a GLP-1, and How Does It Actually Work?
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally produces in response to eating. When you finish a meal, your intestines release GLP-1 into the bloodstream, where it sends a cascade of signals throughout the body. GLP-1 receptor agonists are medications that mimic this hormone, amplifying and extending these effects.
Here's what they do:
They regulate insulin — smartly. GLP-1 stimulates the pancreas to release insulin only when blood sugar is elevated, and suppresses glucagon (the hormone that raises blood sugar). This glucose-dependent action is why GLP-1s carry a very low risk of causing low blood sugar on their own.
They slow gastric emptying. Food moves more slowly from your stomach into your small intestine. This extends the feeling of fullness after eating and prevents sharp blood sugar spikes after meals.
They act on the brain's hunger center. GLP-1 receptors are present in the hypothalamus — the region of the brain that governs appetite and energy balance. These medications reduce food cravings, quiet "food noise," and increase satiety signals, making it genuinely easier to eat less without constant willpower battles.
They work directly on organs throughout the body. GLP-1 receptors exist in the heart, liver, kidneys, and brain — which is why the benefits of these medications extend well beyond blood sugar and weight.
These Medications Are Not New
One of the most important things I want you to hear: GLP-1 medications have been around for nearly two decades. The first GLP-1 receptor agonist, exenatide (Byetta), was FDA-approved in 2005 for type 2 diabetes. Liraglutide followed in 2010, and semaglutide arrived in 2017.
That's 20 years of real-world use, clinical trials, and post-market surveillance data. We are not in uncharted territory. The newer, higher-dose formulations approved specifically for obesity — like Wegovy and Zepbound — have been studied in large, robust trials with tens of thousands of participants over multiple years. We have a lot of safety data, and it is reassuring.
Are GLP-1 Medications Safe?
Yes — when used appropriately, under medical supervision, by the right patients. No medication is risk-free, and GLP-1s are no exception. But the safety profile across two decades of data is strong.
The landmark LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) demonstrated significant reductions in major cardiovascular events — heart attack, stroke, and cardiovascular death — in people with type 2 diabetes and existing heart disease. The SELECT trial in 2023 showed that semaglutide reduced cardiovascular events by 20% even in people without diabetes who had obesity and heart disease — a landmark finding for the field.
Common side effects are mostly gastrointestinal — nausea, vomiting, constipation, diarrhea. These tend to be dose-dependent and temporary, improving as the body adjusts. A slightly elevated risk of pancreatitis and gallbladder disease exists and is monitored. Patients with a personal or family history of medullary thyroid cancer or MEN2 syndrome should not use these medications. The theoretical thyroid C-cell concern seen in rodent studies has not been demonstrated in humans across 20 years of data. In fact, recent reviews of patients taking GLP1 agonists have not shown any increased risk of cancer or pancreatitis.
There is an increased risk for gallstones, this is due to the fact that rapid weight loss can cause gallstones, risk can be reduced by ensuring a safe pace of weight loss.
One thing worth noting: weight loss from any method can involve some muscle loss. This is why I emphasize adequate protein intake and resistance exercise alongside treatment.
The Benefits Go Far Beyond the Scale
Yes, weight loss is significant. Depending on the medication and dose, patients can expect:
Around 15% average body weight loss with semaglutide (Wegovy)
Around 20–22% average body weight loss with tirzepatide (Zepbound)
25% or more in high responders at higher doses
These numbers are not seen with lifestyle intervention alone. The most effective behavioral programs typically achieve 5–10% weight loss with significant effort. This is a meaningful difference.
But the benefits go much further. GLP-1 medications have demonstrated improvements in heart health and reduced risk of heart attack and stroke, fatty liver disease (MASLD/NASH), kidney disease progression, blood pressure, sleep apnea, and markers of systemic inflammation. The FLOW trial in 2024 showed semaglutide significantly slowed chronic kidney disease progression — findings so compelling the trial was stopped early.
Emerging research also points toward possible reductions in dementia risk and certain obesity-related cancers, through reduced inflammation and direct effects on brain tissue. These are active areas of research — promising, and growing.
What About Cost and Coverage?
This is often the biggest barrier — and I won't minimize it. Brand-name GLP-1 medications can cost $900–$1,400 per month without any assistance. That's real, and it matters.
But the landscape is changing.
Insurance coverage varies widely. Many commercial plans cover GLP-1s for type 2 diabetes, and coverage is expanding beyond that. Tirzepatide (Zepbound) is now FDA-approved for obstructive sleep apnea, and semaglutide (Wegovy) carries an indication for cardiovascular risk reduction — both of which have opened new coverage pathways for patients who might not qualify under an obesity diagnosis alone. GLP-1s are also increasingly recognized for their benefit in fatty liver disease (MASLD/NASH), and insurers are beginning to follow the science. Some Medicare Part D plans now cover semaglutide following the SELECT trial data. Coverage is shifting quickly — it's always worth a prior authorization appeal if you're denied, and I help my patients navigate that process.
Cash prices are coming down significantly. With manufacturer savings programs and newer pricing options, many patients are now paying $150–$450 per month out of pocket — a dramatic difference from the sticker price, and increasingly within reach.
And consider the bigger picture: untreated obesity is associated with significantly higher lifetime healthcare costs — diabetes, cardiovascular disease, joint replacement, sleep apnea, cancer. Treating the disease often makes financial sense in the long run.
You Deserve Support — Without Shame
Obesity is recognized by the American Medical Association, the World Health Organization, and every major medical body as a chronic, complex disease. It is not a character flaw. It is not laziness. It is biology — and biology doesn't yield to willpower alone.
The advice to simply "eat less and move more" fails the majority of people with obesity because it ignores the powerful neurohormonal forces that drive hunger, regulate metabolism, and defend the body's weight setpoint. The body actively fights weight loss. That's not weakness. That's physiology.
GLP-1 medications work precisely because they address these underlying biological mechanisms — the same ones your body has been using against you despite your best efforts.
If you've been struggling, if you've tried everything and felt like you were failing — you weren't failing. You were fighting a disease without the right tools.
There is no shame in needing help. You deserve to be supported, to feel well, and to live fully in your body.
Dr. Alejandra Borensztein is a triple board-certified endocrinologist, obesity medicine specialist, and menopause practitioner and the founder of Healthy You Endocrinology & Weight Loss in Collingswood, NJ. She offers in-person and telemedicine appointments across New Jersey and Pennsylvania.